Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 2/20 | 0.31 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4304915 | 0.81 | NR3C2 (0.41) | NR3C2KMT2A | |
| SCHEMBL28810499 | 0.81 | QPCT (0.36) | IGF1RNR3C2 | |
| SCHEMBL501356 | 0.80 | GRM5 (0.41) | — | |
| SCHEMBL1166695 | 0.80 | LOX (0.34) | — | |
| SCHEMBL3921965 | 0.79 | IGF1R (0.44) | IGF1RNR3C2MEN1KMT2A | |
| SCHEMBL2067515 | 0.79 | MAPK1 (0.36) | MEN1KMT2A | |
| SCHEMBL30542327 | 0.78 | LOXL2 (0.47) | IGF1R | |
| SCHEMBL29411261 | 0.78 | RECQL (0.47) | IGF1R | |
| SCHEMBL31139328 | 0.78 | BACE1 (0.34) | BACE1 | |
| SCHEMBL2889185 | 0.78 | LOXL2 (0.47) | IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030100567-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100567-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | IGF1R 107/4885NR3C2 2235/4885NUDT1 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.